Kamada Awarded $22 Million Extension of Canadian Supply Tender
globenewswire.com
news
2022-10-19 00:00:00

Awarded Extension to Existing Supply Tender which relates to Portfolio of Four Specialty IgG Products Acquired in 2021Supply Extension Secures Ongoing Sales of Approximately $7.5 Million Per Year for 2023-2025, with an Option to Extend for up to Additional Two Years REHOVOT, Israel and HOBOKEN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that the Company was awarded an extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM速, HEPAGAM速, VARIZIG速 and WINRHO速 SDF, for an additional three years for an approximate total value of $22 million.
